Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1936-1946

  Kudo Saito, Chie ^a   Wansley, Elizabeth K ^a   Gruys, M Eilene ^a   Wiltrout, Robert ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 15; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INCIDENCE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOWLPOX VIRUS; KIDNEY; KIDNEY CARCINOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; EVALUATION; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOTHERAPY; INTRALESIONAL DRUG ADMINISTRATION; KIDNEY TUMOR; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANIMALS; ANTIGENS, CD58; ANTIGENS, CD80; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; GENE THERAPY; GENETIC VECTORS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-2; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 34250204525     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2398     Document Type: Article

References (59)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-3.
3. Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol 2002;29:41-6.
4. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol 2003;170:178-9.
5. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J Urol 1992;148:1247-8.
6. Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol 2003;44:65-75.
7. Jacobsohn KM, Wood CG. Adjuvant therapy for renal cell carcinoma. Semin Oncol 2006;33:576-82.
8. McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther 2004;4:455-68.
9. McDermott DF, Atkins MB. Interleukin-2 therapy of metastatic renal cell carcinoma - predictors of response. Semin Oncol 2006;33:583-7.
10. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10:6342-6S.
11. Wigginton JM, Komschlies KL, Back TC, et al. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996;88:38-43.
12. + cell responses. J Immunol 2003;170:2727-33.
13. Wiltrout RH, Gregorio TA, Fenton RG, et al. Cellular and molecular studies in the treatment of murine renal cancer. Semin Oncol 1995;22:9-16.
14. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
15. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA1994;271:907-13.
16. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-32.
17. Delahunt B, Wakefield JS. Ultrastructure of streptozotocin-induced renal tumours in mice. Virchows Arch 1997;430:173-80.
18. Gruys ME, Back TC, Subleski J, et al. Induction of transplantable mouse renal cell cancers by streptozotocin: in vivo growth, metastases, and angiogenic phenotype. Cancer Res 2001;61:6255-63.
19. Frankenberger B, Pohla H, Noessner E, et al. Influence of CD80, interleukin-2, and interleukin-7 expression in human renal cell carcinoma on the expansion, function, and survival of tumor-specific CTLs. Clin Cancer Res 2005;11:1733-42.
20. Antonia SJ, Seigne J, Diaz J, et al. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol 2002;167:1995-2000.
21. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8.
22. Hodge JW, Greiner JW, Tsang KY, et al. Costimulatory molecules as adjuvants for immunotherapy. Front Biosci 2006;11:788-803.
23. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-7.
24. + cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther 2004;11:665-80.
25. Panelli MC, Wang E, Marincola FM. The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness. Clin Cancer Res 2005;11:3601-3.
26. Vieweg J, Jackson A. Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin Biol Ther 2004;4:1791-801.
27. Kaufman HL. Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules. Ann N Y Acad Sci 2005;1062:41-50.
28. Kass E, Panicali DL, Mazzara G, Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206-14.
29. McLaughlin JP, Schlom J, Kantor JA, Greiner JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996;56:2361-7.
30. Rosato A, Santa SD, Zoso A, et al. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res 2003;63:2158-63.
31. Kass E, Parker J, Schlom J, Greiner JW. Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen-presenting cells in regional lymph nodes. Cytokine 2000;12:960-71.
32. Huang AY, Gulden PH, Woods AS, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 1996;93:9730-5.
33. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006;6:595-601.
34. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 2002;13:169-83.
35. Waldmann TA, Dubois S, Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001;14:105-10.
36. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005;23:720-31.
37. Gulley J, Arlen P, Dahut W. A pilot study of a PANVAC-V and PANVAC-F in patients (pts) with metastatic carcinoma [abstract]. Proc Am Soc Clin Oncol 2006.
38. Arlen P, Gulley J, Dahut W. A phase 1 study of sequential vaccinations with recombinant fowlpox-PSA (L155)-TRICOM (rF) alone, or in combination with recombinant vaccinia-PSA (L155) (rV); and the role of GM-CSF in patients (pts) with prostate cancer. Proc Am Soc Clin Oncol 2004;23:2522a.
39. Dranoff G, Jaffee E,Lazenby A, etal. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
40. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46.
41. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61:4497-505.
42. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62:5770-7.
43. Kudo-Saito C, Schlom J, Hodge JW. Intratumoral vaccination and diversified subcutaneous/intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules. Clin Cancer Res 2004;10:1090-9.
44. McKee MD, Roszkowski JJ, Nishimura MI. T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med 2005;3:35.
45. Alexander-Miller MA, Leggatt GR, Berzofsky JA. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci U S A 1996;93:4102-7.
46. Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005;174:5994-6004.
47. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 2003;9:1837-49.
48. Liu A, Hu P, Khawli LA, Epstein AL. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy. Clin Cancer Res 2005;11:8492-502.
49. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
50. Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005;11:2416-26.
51. Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 2007;14:942-53.
52. Motzer R, Hutson T, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Am Soc Clin Oncol Annu Meet 2006. p. 24.
53. Escudier B, Szczylic C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Am Soc Clin Oncol Annu Meet 2005. p. 23.
54. Eisen T, Bukowski R, Staehler M, et al. Randomized phase II trial of sorafenib in advanced renal cell carcinoma (RCC): impact of crossover on survival. Am Soc Clin Oncol Annu Meet 2006. p. 24.
55. Shimoyama T, Koizumi F, Fukumoto H, et al. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. Lung Cancer 2006;53:13-21.
56. Pu YS, Hsieh MW, Wang CW, et al. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem Pharmacol 2006;71:751-60.
57. Taira N, Doihara H, Oota T, et al. Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. Acta Med Okayama 2006;60:25-34.
58. Chun PY, Feng FY, Scheurer AM, et al. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 2006;66:981-8.
59. Kobayashi H, Dubois S, Sato N, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005;105:721-7.